CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.
| Autor: | Hicklin DJ; Potenza Therapeutics, Cambridge, Massachusetts. dhicklin@potenzatx.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Apr 01; Vol. 21 (7), pp. 1505-7. |
| DOI: | 10.1158/1078-0432.CCR-14-2553 |
| Abstrakt: | The research article by Prewett and colleagues, published in the May 1, 2002, issue of Clinical Cancer Research, provided important translational data that extended earlier preclinical and clinical studies with the human-murine chimeric anti-EGFR monoclonal antibody C225. Subsequent clinical trials with C225 led to the demonstration of its efficacy in combination with irinotecan and regulatory approval for the treatment of metastatic colorectal cancer. (©2015 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|